RxDoctor Payments Data

Russell Hines, MD

Internal Medicine · Thousand Oaks, CANPI 1548213101

Payments from drug & device makers

$10,045in general payments, 2019–2025

Across 540 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$1K
  • Pfizer$502
  • Astellas Pharma US Inc$440
  • Abbott$437
  • Merck$337
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$9,95599%
  • Education$901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)149$2,488
Amgen(2 entities)66$1,459
Pfizer32$502
Astellas Pharma US Inc16$440
Abbott18$437
Merck18$337
Novartis17$333
Lilly USA, LLC18$316
Johnson & Johnson(2 entities)26$305
GSK13$237
Otsuka America Pharmaceutical, Inc.11$202
Grifols USA, LLC6$162
Sumitomo Pharma America, Inc.3$136
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$122
Novo Nordisk8$121
AstraZeneca7$113
Amarin Pharma, Inc.6$112
Exact Sciences6$94
Genentech USA, Inc.6$87
Alnylam Pharmaceuticals Inc.5$87
Regeneron Healthcare Solutions, Inc.4$87
Nevro Corp.3$86
Radius Health, Inc.5$85
Lucid Diagnostics Inc.5$85
Eisai Inc.5$84
Takeda Pharmaceuticals U.S.A., Inc.7$82
BD4$81
Bayer4$80
Kowa Pharmaceuticals America, Inc.4$75
E.r. Squibb & Sons, L.L.C.3$74
Corcept Therapeutics3$69
Teva Pharmaceuticals USA, Inc.4$68
Lundbeck LLC2$58
Phadia US Inc.2$53
Esperion Therapeutics, Inc.2$48
SK Life Science, Inc.2$45
Duchesnay USA Incorporated2$42
Boston Scientific2$41
Boehringer Ingelheim2$41
Medtronic2$40
Idorsia Pharmaceuticals US Inc2$37
Sanofi-aventis U.S. LLC2$37
Phathom Pharmaceuticals, Inc.2$36
Almatica Pharma LLC2$36
Neurocrine Biosciences, Inc.1$35
Hologic Sales And Service, LLC2$34
Sanofi1$26
Merit Medical Systems Inc1$26
Aimmune Therapeutics, Inc.1$24
Nestle Healthcare Nutrition Inc.1$24
Acadia Pharmaceuticals Inc1$23
Shield Therapeutics Inc1$22
Assertio Therapeutics, Inc.1$22
Arbor Pharmaceuticals, Inc.1$21
Angiodynamics, Inc.1$20
Vertiflex, Inc.1$19
Biohaven Pharmaceuticals, Inc.1$19
Mayne Pharma Commercial LLC1$18
Acerus Pharmaceuticals Corporation1$17
Neos Therapeutics, LP1$16

How this compares

$10,045 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$789,877
Medicare patients
1,018
Services billed
23,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban241$192,226
XareltoRivaroxaban114$104,020
MounjaroTirzepatide58$58,164
JardianceEmpagliflozin60$55,797
FarxigaDapagliflozin Propanediol28$37,689
OzempicSemaglutide20$29,821
ArexvyRsvpref3 Antigen/As01e/Pf88$27,196
TrulicityDulaglutide24$25,500
JanumetSitagliptin Phos/Metformin Hcl39$22,240
JanuviaSitagliptin Phosphate15$18,955
MyrbetriqMirabegron15$17,915
Breo ElliptaFluticasone/Vilanterol25$16,215
NamzaricMemantine Hcl/Donepezil Hcl17$15,001
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$14,612
QuliptaAtogepant25$13,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$502$192,226241 claims
Johnson & JohnsonXarelto$305$104,020114 claims
Lilly USA, LLCMounjaro, Trulicity$316$83,66582 claims
GSKArexvy, Breo Ellipta, Trelegy Ellipta, Anoro Ellipta$237$68,098146 claims
Boehringer IngelheimJardiance, Tradjenta$41$65,04271 claims
MerckJanumet, Januvia, Janumet Xr$337$48,51368 claims
AstraZenecaFarxiga, Brilinta$113$43,07241 claims
AbbVieNamzaric, Qulipta, Synthroid$2,488$38,940219 claims
Novo NordiskOzempic$121$29,82120 claims
Astellas Pharma US IncMyrbetriq$440$17,91515 claims
Sanofi-aventis U.S. LLCMultaq$37$10,92314 claims
BayerKerendia$80$7,52911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Thousand Oaks

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →